Peter P. Nghiem, DVM, PhD, Texas A&M University
Peter P. Nghiem, DVM, PhD
The current research focus in the Nghiem laboratory is on preclinical drug trials, including gene therapy (dystrophin gene replacement) via adeno-associated viral vector delivery; utilzing gene editing techniques such as CRISPR/Cas9 and TALENs for treatments of genetic disease; characterization of genetic modifiers via whole-genome next generation sequencing (discovery approach); and evaluation of muscle metabolism in dystrophin deficiency.
Products
References
- López SM, Balog-Alvarez C, Canessa EH, Hathout Y, Brown KJ, Vitha S, Bettis AK, Boehler J, Kornegay JN, Nghiem PP. Creation and characterization of an immortalized canine myoblast cell line: Myok9. Mamm Genome. 2020 Apr;31(3-4):95-109. doi: 10.1007/s00335-020-09833-5. Epub 2020 Apr 3. PMID: 32246189.
